Abstract:The varied ways in which mutations in presenilins (PSEN1 and PSEN2) affect amyloid β precursor protein (APP) processing in causing early–onset familial Alzheimer disease (FAD) are complex and not properly understood. Many recent lines of evidence also suggest that clinical PSEN mutations, in addition to increasing Aβ42 can also cause PSEN loss of function. (1) To develop a highly reproducible in vitro assay for not only comparing Aβ42/Aβ40 ratio between different PSEN mutations, but also evaluating individual contributions of Aβ42 and Aβ40 to this ratio. (2) To test whether PSEN mutations cause a clinically relevant increase in Aβ42 or a decrease in Aβ40, and whether these changes corroborate with brain depositions. Aβ and APP processing were studied for a well–represented set of nine clinical PSEN mutations (PSEN1– A79V, I143T, A231V, L262F, C263F, L282V, G384A, Δ9 and PSEN2– N141I) on a novel, ELISA–based in vitro assay. The assay was well–normalized for PSEN and APP/Sw transfection and also for cellular viability. Correlations were made with mean age–of–onset. Brain Aβ40 and Aβ42 levels in 6 mutations were also analyzed by image densitometry and mass spectrometry, and were correlated with the in vitro data. All mutations significantly increased Aβ42/Aβ40 in vitro by significantly decreasing Aβ40 with accumulation of APP C–terminal fragments, a sign of decreased PSEN activity. Aβ42 was also significantly elevated for PSEN1– I143T, G384A, Δ9, and PSEN2– N141I. Age–of–onset of PSEN1–linked FAD correlated inversely with Aβ42/Aβ40 (r = – 0.89; P = 0.001) and absolute levels of Aβ42 (r = – 0.83; P = 0.006), but directly with Aβ40 levels (r = 0.69; P = 0.035). These changes also partly correlated with brain Aβ levels. Our data suggest that a decrease of Aβ40 by FAD–linked PSEN mutations is perhaps as important as an increase in Aβ42. The direct correlation of Aβ40 with age–of–onset suggests that Aβ40 might be protective by perhaps sequestering the more toxic Aβ42 and facilitating its clearance. Also, the in vitro method we describe here is a valid tool for assaying the pathogenic potential of clinical PSEN mutations in a molecular diagnostic setting.

The presenilin 1 mutation P436S causes familial Alzheimer's disease with elevated Aβ43 and atypical clinical manifestations

A heterozygous de novo PSEN1 mutation in a patient with early-onset parkinsonism

P3-395: Mean Age-of-onset of Familial Alzheimer Disease Caused by Presenilin Mutations Correlates with Both Increased Aβ42 and Decreased Aβ40

Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio in Vitro and in Vivo

Mean Age-Of-Onset of Familial Alzheimer Disease Caused by Presenilin Mutations Correlates with Both Increased A Beta 42 and Decreased A Beta 40

A Novel Presenilin 1 Mutation (F388L) Identified in a Chinese Family with Early-Onset Alzheimer's Disease.

Cholinergic-like neurons and cerebral spheroids bearing the PSEN1 p.Ile416Thr variant mirror Alzheimer's disease neuropathology

The E280A Presenilin 1 Alzheimer Mutation Produces Increased Aβ42 Deposition and Severe Cerebellar Pathology

A Pathogenic Variant p.Phe177Val in PSEN1 Causes Early-Onset Alzheimer’s Disease in a Chinese Family

Presenilin‐1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage

Pathological and Physiological Functions of Presenilins

A New Presenilin 1 (Psen1) Mutation (p.Cys263Trp) as a Cause of Both Early and Late-Onset Alzheimer's Disease in a Large Italian Family

Identification of a Rare <i>PSEN1</i> Mutation (Thr119Ile) in Late-Onset Alzheimer's Disease With Early Presentation of Behavioral Disturbance

Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

Presenilin 1 Mutations Linked to Familial Alzheimer's Disease Increase the Intracellular Levels of Amyloid Β‐protein 1–42 and Its N‐Terminally Truncated Variant(s) Which Are Generated at Distinct Sites

Genetic Influences on White Matter and Metabolism Abnormal Change in Alzheimer's Disease: Meta-analysis for Neuroimaging Research on Presenilin 1 Mutation

The identification of PSEN1 p.Tyr159Ser mutation in a non-canonic early-onset Alzheimer's disease family

Mutations in PSEN1 predispose inflammation in an astrocyte model of familial Alzheimer's disease through disrupted regulated intramembrane proteolysis

Patient with PSEN1 Glu318Gly and Other Possible Disease Risk Mutations, Diagnosed with Early Onset Alzheimer's Disease

Familial Alzheimer's Disease Neurons Bearing Mutations in PSEN1 Display Increased Calcium Responses to AMPA as an Early Calcium Dysregulation Phenotype

Neuropathology of patients with preclinical or early clinical Alzheimer's disease with pathogenic PSEN1_p. L392V: Comparison of advanced siblings